Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-03-04

FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for the fixed-dose combination of losartan potassium and hydrochlorothiazide by Teva Pharmaceuticals USA, Inc., ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Losartan potassium and hydrochlorothiazide (losartan potassium and hydrochlorothiazide)

Snippet

SUPPL AP for LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)